Desimone JA et al. |
Treatment of Mycobacterium avium complex immune reconstitution disease in HIV-1-infected individuals. |
2003 |
AIDS Patient Care STDS |
pmid:14746655
|
|
Different clarithromycin doses affect mortality. |
1997 |
AIDS Patient Care STDS |
pmid:11361754
|
Aboulafia DM |
Thalidomide-based treatment for HIV-associated multiple myeloma: a case report. |
2003 |
AIDS Read |
pmid:14524324
|
Kahlon SS et al. |
Mycobacterium-avium-intracellulare complex immune reconstitution inflammatory syndrome in HIV/AIDS presenting as osteomyelitis. |
2008 |
AIDS Read |
pmid:18975441
|
Chu J et al. |
Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV. |
2011 |
AIDS Res Ther |
pmid:21388558
|
Smibert OC et al. |
Short Communication: Mycobacterium avium Complex Infection and Immune Reconstitution Inflammatory Syndrome Remain a Challenge in the Era of Effective Antiretroviral Therapy. |
2017 |
AIDS Res. Hum. Retroviruses |
pmid:28791872
|
Katelaris PH et al. |
Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10848659
|
Ammon S et al. |
Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10848660
|
Sharara AI et al. |
Letter: clarithromycin dose for H. pylori therapy remains unresolved--authors' reply. |
2015 |
Aliment. Pharmacol. Ther. |
pmid:26238584
|
Gisbert JP and Calvet X |
Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. |
2012 |
Aliment. Pharmacol. Ther. |
pmid:22129228
|
Lehmann FS et al. |
Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10735923
|
Malfertheiner P et al. |
Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12969088
|
Malfertheiner P et al. |
Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11860399
|
Huang J and Hunt RH |
The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10383500
|
Miwa H et al. |
Impact of rabeprazole, a new proton pump inhibitor, in triple therapy for Helicobacter pylori infection-comparison with omeprazole and lansoprazole. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10383502
|
Dobrilla G et al. |
Ranitidine bismuth citrate with either clarithromycin 1 g/day or 1.5 g/day is equally effective in the eradication of H. pylori and healing of duodenal ulcer. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9692703
|
Ott EA et al. |
Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15882244
|
Chen PY et al. |
Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply. |
2017 |
Aliment. Pharmacol. Ther. |
pmid:28074519
|
Gisbert JP and Pajares JM |
Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12030945
|
Laine L and Dhir V |
Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:12030957
|